ES2694001T3 - Moduladores de LXR - Google Patents
Moduladores de LXR Download PDFInfo
- Publication number
- ES2694001T3 ES2694001T3 ES14770510T ES14770510T ES2694001T3 ES 2694001 T3 ES2694001 T3 ES 2694001T3 ES 14770510 T ES14770510 T ES 14770510T ES 14770510 T ES14770510 T ES 14770510T ES 2694001 T3 ES2694001 T3 ES 2694001T3
- Authority
- ES
- Spain
- Prior art keywords
- cycloalkyl
- alkyl
- monocyclic
- ring
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787422P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/027679 WO2014152738A1 (en) | 2013-03-15 | 2014-03-14 | Lxr modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2694001T3 true ES2694001T3 (es) | 2018-12-17 |
| ES2694001T9 ES2694001T9 (es) | 2019-07-12 |
Family
ID=51581300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14770510T Active ES2694001T3 (es) | 2013-03-15 | 2014-03-14 | Moduladores de LXR |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9751869B2 (https=) |
| EP (1) | EP2967073B9 (https=) |
| JP (1) | JP6456909B2 (https=) |
| CN (1) | CN105188380B (https=) |
| ES (1) | ES2694001T3 (https=) |
| WO (1) | WO2014152738A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105209039B (zh) | 2013-03-15 | 2018-06-22 | 百时美施贵宝公司 | Lxr调节剂 |
| ITUA20164199A1 (it) * | 2016-06-08 | 2017-12-08 | Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro | Modulatori di soce compisizioni e relativi usi |
| WO2018091389A1 (en) | 2016-11-17 | 2018-05-24 | Syngenta Participations Ag | Pesticidally active heterocyclic derivatives with sulphur containing substituents |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| CN113457708B (zh) * | 2021-06-30 | 2023-10-20 | 常州大学 | CoN@C多孔材料及其制备方法以及在芳香族腈类化合物的合成中的应用 |
| KR20250030474A (ko) * | 2022-06-10 | 2025-03-05 | 시오나 테라퓨틱스 인크. | 화합물, 조성물 및 이의 사용 방법 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE252290T1 (de) | 1986-06-10 | 1988-06-09 | Chiesi Farmaceutici S.P.A., Parma | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
| US5434178A (en) * | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
| US5908852A (en) | 1994-11-14 | 1999-06-01 | G. D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
| CN100513570C (zh) | 1999-06-18 | 2009-07-15 | Cv治疗公司 | 结合框运输蛋白abc1的调节作用 |
| WO2001082917A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Treatment of hypertriglyceridemia and other conditions using lxr modulators |
| US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
| EP1465869B1 (en) | 2001-12-21 | 2013-05-15 | Exelixis Patent Company LLC | Modulators of lxr |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| US7247735B2 (en) | 2002-07-26 | 2007-07-24 | Infineon Technologies Ag | Octupolar molecules used as organic semiconductors |
| AU2003293376A1 (en) | 2002-12-10 | 2004-06-30 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
| MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| CA2522476A1 (en) | 2003-04-18 | 2004-11-04 | Merck & Co., Inc. | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers |
| US8318760B2 (en) * | 2005-03-21 | 2012-11-27 | Merck Sharp & Dohme Corp. | Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use |
| BRPI0612287A8 (pt) | 2005-06-27 | 2019-01-22 | Exelixis Inc | composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| KR101676704B1 (ko) | 2009-05-28 | 2016-11-16 | 엑셀리시스 페이턴트 컴퍼니 엘엘씨 | Ｌｘｒ 조절자 |
| SG10201607345YA (en) * | 2012-03-02 | 2016-11-29 | Ralexar Therapeutics Inc | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
| CN105209039B (zh) | 2013-03-15 | 2018-06-22 | 百时美施贵宝公司 | Lxr调节剂 |
-
2014
- 2014-03-14 JP JP2016502514A patent/JP6456909B2/ja not_active Expired - Fee Related
- 2014-03-14 ES ES14770510T patent/ES2694001T3/es active Active
- 2014-03-14 US US14/774,839 patent/US9751869B2/en not_active Expired - Fee Related
- 2014-03-14 EP EP14770510.7A patent/EP2967073B9/en active Active
- 2014-03-14 WO PCT/US2014/027679 patent/WO2014152738A1/en not_active Ceased
- 2014-03-14 CN CN201480027521.4A patent/CN105188380B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2967073A1 (en) | 2016-01-20 |
| JP6456909B2 (ja) | 2019-01-23 |
| CN105188380B (zh) | 2017-08-15 |
| EP2967073B1 (en) | 2018-08-01 |
| ES2694001T9 (es) | 2019-07-12 |
| CN105188380A (zh) | 2015-12-23 |
| JP2016518334A (ja) | 2016-06-23 |
| US20160289222A1 (en) | 2016-10-06 |
| WO2014152738A1 (en) | 2014-09-25 |
| EP2967073B9 (en) | 2019-04-10 |
| US9751869B2 (en) | 2017-09-05 |
| EP2967073A4 (en) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2694001T3 (es) | Moduladores de LXR | |
| AR129635A2 (es) | Moduladores de tetrahidropiridopirazina de gpr6 | |
| PE20190329A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR106314A1 (es) | COMPUESTOS DE ESPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53 | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| AR100691A1 (es) | Esteroides neuroactivos, composiciones, y usos de los mismos | |
| AR106806A1 (es) | Inhibidores triazol de acc y usos de los mismos | |
| CR20180578A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| AR101600A1 (es) | COMPUESTOS DE SPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2-p53 | |
| UY36838A (es) | Compuestos heterocíclicos moduladores de la señalización de tnf alfa y composiciones farmacéuticas que los contienen | |
| CL2020000610A1 (es) | Compuestos de bisamida que activan el sarcómero y sus usos. | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR096242A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR106863A1 (es) | Compuestos de bencimidazol inhibidores de pad4 | |
| AR101558A1 (es) | Difluoropirrolidinas como moduladores del receptor de orexina | |
| AR096241A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| PE20180482A1 (es) | Oxiesteroles y metodos de uso de los mismos | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| JOP20170169A1 (ar) | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR075368A1 (es) | Inhibidores de glicosilceramida sintasa | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| PE20181074A1 (es) | Compuestos heteroaromaticos como inhibidores de btk | |
| AR105668A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 |